Clinical trial · Interventional
A Pharmacokinetic Study of Valacyclovir in Pediatric Oncology Patients
NCT00042328CI-TRIAL-00018921completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research is to study the pharmacology (how the body handles this drug) of valacyclovir in children receiving treatment for cancer. This study will last approximately 7 days.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Valacyclovir | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 2 Years
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: * Age: Patients must be \> / = 2 and \< / = 18 years old. * Life Expectancy: Patients must have a life expectancy of \> 8 weeks * Subjects must have a diagnosed malignancy, and must currently be receiving consolidation or maintenance chemotherapy * Hepatic/Renal Function: Patients must have adequate hepatic function (bilirubin \< / = 1.5 mg/dl: SGPT \< 3x normal) and adequate renal function (creatinine \< / = 1 mg/dl: BUN \< 20 ) * Medication Tolerance: Patients must be able to swallow pills or tolerate a suspension of the medication * Fluid Tolerance: Children must be able to retain liquids at the time of enrollment * Informed Consent: Written informed consent will be obtained from all patients and/or their parents prior to enrollment * Pregnancy: Women of childbearing age must have a negative serum pregnancy test at the time of study entry Exclusion criteria: * More than one prior chemotherapy regimen. * Patients with uncontrolled infections. * Subjects with known history of adverse reaction to acyclovir in the past. * Patients with concurrent infections requiring treatment with valacyclovir or acyclovir.
References
Publications (0)
Data not yet available
No reference posted for this study.